Sherene Loi

Sep 11, 2024 | nature.com | Seock-Ah Im |Javier Cortés |David W. Cescon |Norikazu Masuda |Toshimi Takano |Chiun-Sheng Huang | +6 more

AbstractIn the phase 3 KEYNOTE-355 study (NCT02819518), pembrolizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) versus placebo plus chemotherapy among patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) and programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 10 tumors.

Aug 20, 2024 | nature.com | Daniel G. Stover |Roberto Salgado |Sherene Loi |W. Fraser Symmans |Charles M. Perou |Lisa Carey

AbstractAssociation of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free survival in randomized phase III trial CALGB 40502.

Aug 7, 2024 | cancernetwork.com | Chiun-Sheng Huang |Miguel Cabral Martin |Miguel Martín |Sherene Loi |Michael Untch

BackgroundInterim results from the phase 3 NATALEE trial showed that ribociclib added to standard-of-care adjuvant nonsteroidal aromatase inhibitor (NSAI) had a significant invasive disease-free survival (iDFS) benefit in patients with stage II/III HR+/HER2- early breast cancer (EBC) at risk of recurrence, including those with node-negative disease. We present the final protocol-specified analysis of iDFS (primary end point).

Nov 3, 2023 | nature.com | Mattia Rediti |Katherine A. Hoadley |Joel Parker |David Hillman |Martine Piccart |Serena Di Cosimo | +6 more

AbstractThe identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigate the complexity of B and T cell receptor (BCR and TCR) repertoires in the context of two phase III trials, NeoALTTO and CALGB 40601, evaluating neoadjuvant paclitaxel with trastuzumab and/or lapatinib in women with HER2-positive breast cancer.

Jul 21, 2023 | allevents.in | Sherene Loi

Select Your City We have got 40,000 cities covered worldwide Discover Events from nearby cities South Yarra Geelong Prahran Bendigo Ballarat Hawthorn Ascot Vale Mornington Footscray Preston Discover Online Events - Attend from anywhere → Time Fri Nov 24 2023 at 12:30 pm to 06:00 pm (GMT+11:00) Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Australia About the event Peter Mac Breast Cancer Medical Oncology Education Day The Peter Mac Medical Oncology Breast Education Day will be...